Consistent concomitant use of proton pump inhibitors (PPIs) with elbasvir/grazoprevir (EBR/GZR) had no clinically significant effect on 12-week sustained viral response (SVR12) rates in patients with hepatitis C virus (HCV) genotype (GT)1 or GT4 infection with and without cirrhosis, according to research presented at The Liver Meeting® 2016
Direct-acting antiviral (DAA) therapy “has an exemplary safety profile across a broad population of patients treated in usual clinical practice,” reported study authors at The Liver Meeting® 2016.
The prevalence of chronic liver diseases has more than doubled in the past 30 years among adolescents and young adults in the United States to about 25%, according to research presented at The Liver Meeting® 2016.
Data from a post-hoc analysis shows no additional safety concerns with obeticholic acid in a subgroup of patients with cirrhosis, according to a presentation at The Liver Meeting® 2016.
For adolescents with chronic hepatitis C virus (HCV) infection, treatment with sofosbuvir (SOF) and ribavirin (RBV) led to a 98% SVR12 rate with no virologic failures, reported Kathleen B. Schwarz, MD, a professor of pediatrics at Johns Hopkins University School of Medicine, Baltimore, MD, at The Liver Meeting® 2016.
Fenofibrate has the potential to reduce hepatic inflammation by decreasing production of pro-inflammatory cytokines and may “exert human anti-cholestatic actions through its anti-inflammatory mechanisms.”
With international travel, “any outbreak, anywhere in the world can be a threat, everywhere.” That’s the reality of an increasingly connected world, said Malik Peiris, PhD, of the School of Public Health at the HKU-Pasteur Research Center, The University of Hong Kong, Pokfulam, Hong Kong, at IDWeek 2016.
Long-term use of proton pump inhibitors (PPIs) might increase microbial translocation and innate immune activation but not enterocyte turnover or T-cell activation among people infected with HIV-1, according to research findings reported at IDWeek 2016.
Together, depression and HIV infection are “strongly associated” with all-cause mortality in U.S. veterans, results from one of the largest analyses to date to examine this association reported at IDWeek 2016.